financetom
Business
financetom
/
Business
/
German appeals court denies claims against physician giving COVID vaccine
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
German appeals court denies claims against physician giving COVID vaccine
Jun 25, 2024 6:52 AM

FRANKFURT, June 25 (Reuters) - An appeals court in the

German city of Stuttgart on Tuesday rejected damage claims

against a physician who was accused of not warning of alleged

harm from a COVID-19 vaccine she administered.

The higher regional court in the city of Stuttgart said in a

statement said the verdict was the first such ruling by a German

appeals court.

It said that a trainee in a care facility did not succeed

with her claims seeking at least 50,000 euros ($53,545.00) in

injury awards plus unspecified damages claims from a physician

who administered two shots by the BioNTech-Pfizer

alliance.

A slew of damage claims in German courts against COVID

vaccine makers, citing alleged side effects, have so far not

succeeded.

($1 = 0.9338 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Analysis-Germany talks tough but has limited room to halt UniCredit's advance on Commerzbank
Analysis-Germany talks tough but has limited room to halt UniCredit's advance on Commerzbank
Oct 3, 2024
BERLIN/FRANKFURT (Reuters) - UniCredit Chief Executive Andrea Orcel has succeeded in uniting Germany's political establishment in opposition to his stakebuilding in Commerzbank, the country's second largest lender. The bad news for Germany's angry politicians is that they have few options to halt the ambitious Orcel, who appears to have his sights fixed on a transformative deal for the European banking...
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug
Oct 3, 2024
On Tuesday, Wave Life Sciences Ltd. ( WVE ) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping. DMD is a genetic disease that causes progressive muscle weakness and degeneration caused by a mutation in the dystrophin gene. It’s the most common inherited neuromuscular disease and affects...
China ADRs, miners, casino shares leap as Beijing launches fresh stimulus measures
China ADRs, miners, casino shares leap as Beijing launches fresh stimulus measures
Oct 3, 2024
(Reuters) - U.S.-listed shares of Chinese firms jumped on Tuesday, along with China-focused exchange-traded funds, casino companies and commodity-linked stocks, as Beijing's largest stimulus measures since the pandemic raised hopes of renewed growth. The People's Bank of China unveiled a raft of policy measures, including interest rate cuts, a reduction in mortgage rates and new tools to boost capital market...
Legacy Housing Insider Sold Shares Worth $403,183, According to a Recent SEC Filing
Legacy Housing Insider Sold Shares Worth $403,183, According to a Recent SEC Filing
Oct 3, 2024
11:17 AM EDT, 09/24/2024 (MT Newswires) -- Curtis Drew Hodgson, 10% Owner, Director, Chairman of the Board, on September 23, 2024, sold 14,420 shares in Legacy Housing ( LEGH ) for $403,183. Following the Form 4 filing with the SEC, Hodgson has control over a total of 4,402,477 shares of the company, with 633,421 shares held directly and 3,769,056 controlled...
Copyright 2023-2025 - www.financetom.com All Rights Reserved